AR081736A1 - COMPOSICIONES SOLIDAS QUE COMPRENDEN (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA - Google Patents

COMPOSICIONES SOLIDAS QUE COMPRENDEN (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA

Info

Publication number
AR081736A1
AR081736A1 ARP110100756A ARP110100756A AR081736A1 AR 081736 A1 AR081736 A1 AR 081736A1 AR P110100756 A ARP110100756 A AR P110100756A AR P110100756 A ARP110100756 A AR P110100756A AR 081736 A1 AR081736 A1 AR 081736A1
Authority
AR
Argentina
Prior art keywords
dioxo
carboxamide
methylpirazin
hexadecahydrociclopropa
diazaciclopentadecin
Prior art date
Application number
ARP110100756A
Other languages
English (en)
Inventor
Leena Prasad
Bernd Liepold
Karin Rosenblatt
Eric A Schmitt
Jonathan Miller
John B Morris
Peter Hlig
Rajeev Gokhale
Original Assignee
Abbott Lab
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Enanta Pharm Inc filed Critical Abbott Lab
Publication of AR081736A1 publication Critical patent/AR081736A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Reivindicación 1: Una composición sólida caracterizada porque comprende (i) (2R,6S,13aS,14aR,16aS,Z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida, o una sal farmacéuticamente aceptable de ésta, en una forma amorfa; (ii) un polímero hidrofílico farmacéuticamente aceptable; y (iii) un agente tensioactivo farmacéuticamente aceptable.Reivindicación 15: La composición de la reivindicación 1, caracterizada porque también comprende ritonavir.
ARP110100756A 2010-03-10 2011-03-10 COMPOSICIONES SOLIDAS QUE COMPRENDEN (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA AR081736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10

Publications (1)

Publication Number Publication Date
AR081736A1 true AR081736A1 (es) 2012-10-17

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100756A AR081736A1 (es) 2010-03-10 2011-03-10 COMPOSICIONES SOLIDAS QUE COMPRENDEN (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA

Country Status (27)

Country Link
US (1) US20110312973A1 (es)
EP (1) EP2544689B1 (es)
JP (2) JP5717768B2 (es)
KR (1) KR101579079B1 (es)
CN (2) CN104771364B (es)
AR (1) AR081736A1 (es)
AU (1) AU2011224558B2 (es)
BR (1) BR112012022774A2 (es)
CA (1) CA2792601C (es)
CL (1) CL2012002500A1 (es)
CO (1) CO6640208A2 (es)
DO (1) DOP2012000245A (es)
EA (1) EA021570B1 (es)
EC (1) ECSP12012148A (es)
ES (1) ES2613608T3 (es)
GT (1) GT201200257A (es)
IL (1) IL221833A (es)
MX (1) MX2012010478A (es)
MY (1) MY156888A (es)
NZ (1) NZ602288A (es)
PE (1) PE20130198A1 (es)
SG (1) SG183985A1 (es)
TW (1) TWI490218B (es)
UA (1) UA104517C2 (es)
UY (1) UY33265A (es)
WO (1) WO2011112558A2 (es)
ZA (1) ZA201207093B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20227342B (en) * 2010-07-12 2022-01-25 Salix Pharmaceuticals Ltd Us Formulations of rifaximin and uses thereof
KR20140003521A (ko) * 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2847355A1 (en) * 2011-09-16 2013-03-21 Abbvie Inc. Methods for treating hcv
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2015100275B4 (en) * 2011-10-21 2015-06-11 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
ES2572330B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa (aad) para su uso en el tratamiento del vhc
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) * 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
EP2866807A2 (en) * 2012-06-27 2015-05-06 Abbvie Inc. Methods for treating hcv
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
MX2015000535A (es) * 2012-07-12 2015-05-11 Abbvie Inc Formas cristalinas de un inhibidor de vhc.
PL3725778T3 (pl) * 2012-09-11 2021-12-20 Medivation Prostate Therapeutics Llc Preparaty enzalutamidu
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
US20150175612A1 (en) * 2013-12-04 2015-06-25 Abbvie Inc. Crystal forms
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015116594A1 (en) 2014-01-28 2015-08-06 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
JP6831704B2 (ja) * 2014-06-18 2021-02-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 非イオン界面活性剤を含む新規の薬学的組成物
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
TWI604859B (zh) * 2015-08-28 2017-11-11 康霈生技股份有限公司 用於減少局部脂肪的醫藥組成物及其用途
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3518924B1 (en) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
AU2018236349B2 (en) * 2017-03-15 2021-03-11 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
SG11202105572UA (en) 2018-11-30 2021-06-29 Chemocentryx Inc Capsule formulations
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
UA81028C2 (en) * 2003-04-02 2007-11-26 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis c viral protease inhibitors
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
WO2006036614A2 (en) * 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
TWI383980B (zh) * 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
WO2009080542A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US20110207660A1 (en) * 2008-08-07 2011-08-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由５，６－二氫－１ｈ－吡啶－２－酮與一或多種其他抗病毒化合物的組合物抑制ｃ型肝炎病毒的方法
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
US20110312973A1 (en) 2011-12-22
NZ602288A (en) 2014-02-28
DOP2012000245A (es) 2013-02-15
CN104771364A (zh) 2015-07-15
EP2544689A2 (en) 2013-01-16
KR101579079B1 (ko) 2015-12-21
JP5890553B2 (ja) 2016-03-22
EP2544689B1 (en) 2017-01-11
CN103118681B (zh) 2015-02-18
MX2012010478A (es) 2013-02-01
MY156888A (en) 2016-04-15
JP5717768B2 (ja) 2015-05-13
CO6640208A2 (es) 2013-03-22
ECSP12012148A (es) 2012-10-30
EA201290892A1 (ru) 2013-03-29
TWI490218B (zh) 2015-07-01
AU2011224558B2 (en) 2014-02-27
EA021570B1 (ru) 2015-07-30
UY33265A (es) 2011-10-31
PE20130198A1 (es) 2013-03-24
JP2015145387A (ja) 2015-08-13
ES2613608T3 (es) 2017-05-24
ZA201207093B (en) 2013-05-29
TW201202239A (en) 2012-01-16
CA2792601C (en) 2015-09-29
IL221833A (en) 2017-01-31
BR112012022774A2 (pt) 2017-09-12
CL2012002500A1 (es) 2012-12-07
CN103118681A (zh) 2013-05-22
EP2544689A4 (en) 2014-04-02
WO2011112558A2 (en) 2011-09-15
AU2011224558A1 (en) 2012-09-27
CN104771364B (zh) 2018-05-25
GT201200257A (es) 2014-09-26
CA2792601A1 (en) 2011-09-15
JP2013522208A (ja) 2013-06-13
SG183985A1 (en) 2012-10-30
WO2011112558A3 (en) 2012-01-05
UA104517C2 (uk) 2014-02-10
KR20130048210A (ko) 2013-05-09

Similar Documents

Publication Publication Date Title
AR081736A1 (es) COMPOSICIONES SOLIDAS QUE COMPRENDEN (2R,6S,13aS,14aR,16aS,Z)-N-(CICLOPROPILSULFONIL)-6-(5-METILPIRAZIN-2-CARBOXAMIDO)-5,16-DIOXO-2-(FENANTRIDIN-6-ILOXI)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-HEXADECAHIDROCICLOPROPA[E]PIRROLO[1,2-a][1,4]DIAZACICLOPENTADECIN-14a-CARBOXAMIDA
CL2011000512A1 (es) (2r,6s,13as,14ar,16as,z)-n- (ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida y composicion farmaceutica que lo comprende.
CL2008001122A1 (es) Compuestos derivados de imidazo[1,2,3-ij]-1,8-naftiridin-4,9-diona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de infecciones bacterianas.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
IL192373A (en) Arginine cyclic peptides and their use in the treatment of fungal infections
CL2008001274A1 (es) Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
SMT201400003B (it) Derivati di 1,2,4-triazolo[4,3-A]piridina e loro uso per il trattamento o la prevenzione di disturbineurologici e psichiatrici
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2011000480A1 (es) Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras.
WO2006128167A3 (en) Optical coherence tomographic detection of cells and compositions
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
WO2007034196A3 (en) Imaging agents comprising silicon
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
ECSP088425A (es) INHIBIDORES DE LA ACTIVIDAD Akt
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
AR060165A1 (es) Proteina de suero como vehiculo de entrega para un agente activo
WO2013059530A3 (en) Peptidomimetic macrocycles
IL206466A0 (en) PYRAZOLO [1,5-a]PYRIMIDINES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF

Legal Events

Date Code Title Description
FB Suspension of granting procedure